Cibus, Inc. (CBUS) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates a positive outlook with significant cost reductions, improved net loss, and strategic focus on future revenue streams, particularly from rice herbicide traits and biofragrance programs. The Q&A reveals optimism about R&D collaborations, regulatory progress, and market potential, despite some uncertainties in financing specifics. The strong potential for royalty revenue and commercial expansion, coupled with reduced expenses, suggests a positive stock movement over the next two weeks.
Key Financial Performance
Cash and Cash Equivalents $23.9 million as of September 30, 2025. This is expected to fund planned operating expenses and capital expenditure requirements into early Q2 2026, reflecting cost-saving initiatives.
Revenue $615,000 for Q3 2025, compared to $1.7 million in Q3 2024. This decrease is due to the timing of partner-funded program activities.
Research and Development Expense $10.8 million for Q3 2025, compared to $13 million in Q3 2024. This $2.2 million decrease is primarily due to cost reduction initiatives.
Selling, General and Administrative Expense $5.2 million for Q3 2025, compared to $7.7 million in Q3 2024. This $2.5 million decrease is primarily due to cost reduction initiatives.
Net Loss $24.3 million for Q3 2025, compared to $201.5 million in Q3 2024. The significant improvement reflects a $181.4 million noncash goodwill impairment charge taken in Q3 2024.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Rice herbicide tolerance traits (HT1 and HT3): Signed 7 customer agreements in the USA and Latin America, representing 5-7 million addressable acres and over $200 million in potential annual royalties. Initial commercial launch in Latin America is targeted for 2027, followed by the US in 2028 and Asia by 2030.
Biofragrance products: Completed pre-commercial pilot runs for 2 biofragrance products, validating readiness for full commercial scale. Initial payments received in Q4 2025, with targeted expansion in 2026.
Expansion into Latin America and India: Signed agreements with Latin American partners, including CIAT and FLAR, to expand rice herbicide tolerance traits. Collaborating with AgVaya to access Indian markets, targeting 120 million acres of rice cultivation.
Global regulatory progress: Positive regulatory developments in the EU, North and South America, India, and Asia. Approval for gene-edited rice planting in California.
Cost-saving initiatives: Reduced operating expenses by $5 million in the first 9 months of 2025. Consolidated facilities to streamline operations, targeting $30 million in annual net cash usage by 2026.
RTDS platform: Standardized Rapid Trait Development System (RTDS) enables editing of elite germplasm within 12-15 months, driving commercial partnerships and customer expansion.
Streamlined strategic focus: Focused on high-value near-term revenue opportunities, particularly in rice herbicide tolerance traits and biofragrance products.
Board appointments: Added Kimberly Box and Craig Wichner to the Board, bringing expertise in technology operations, strategic transformation, and sustainable agriculture to support commercialization efforts.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The EU regulatory process for new genomic techniques is still active and undergoing refinement, which could delay market access. Additionally, while there is progress in regulatory clarity in India and parts of Asia, these processes are not yet finalized, posing potential risks to global market access.
Financial Sustainability: The company has $23.9 million in cash and cash equivalents, which is expected to fund operations only until early Q2 2026. This creates a risk of insufficient funding for planned commercialization and operational goals if additional financing is not secured.
Revenue Decline: Revenue for Q3 2025 decreased to $615,000 from $1.7 million in the same period last year, reflecting timing issues in partner-funded program activities. This decline could impact short-term financial stability.
Operational Consolidation Risks: The consolidation of facilities and reduction in workforce, while aimed at cost savings, could disrupt operations or delay progress if not managed effectively.
Market Entry Challenges: The company’s commercialization timeline for Rice traits targets Latin America in 2027, the U.S. in 2028, and Asia closer to 2030. Delays in these timelines or failure to meet market expectations could impact revenue projections.
Competitive Pressures: The gene editing space is highly competitive, and the company’s ability to maintain its technological edge with its RTDS platform is critical. Failure to do so could result in loss of market share.
Economic Uncertainties: Global economic conditions, including potential recessions or changes in agricultural funding, could impact the adoption of the company’s products and its financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Rice herbicide tolerance traits (HT1 and HT3): Targeted initial commercial launch in Latin America in 2027, expansion to the United States in 2028, and Asia closer to 2030. Potential to capture over $200 million in annual royalties.
Biofragrance program: Initial payments expected in Q4 2025, with targeted expansion throughout 2026. Positioned for full commercialization in subsequent years.
Regulatory advancements: Positive regulatory developments in the EU, North and South America, India, and parts of Asia are creating a foundation for global market access. Approval for gene-edited rice planting in California achieved.
Capital allocation and financial outlook: Targeting approximately $30 million in annual net cash usage for 2026. Existing cash expected to fund operations into early Q2 2026.
Commercialization progress: Seven Rice customer agreements signed in the USA and Latin America, representing 5-7 million addressable acres. Initial field validation trials in Latin America expected by year-end 2025.
RTDS platform: Standardized Rapid Trait Development System (RTDS) enables editing of elite germplasm within 12-15 months, driving commercial partnerships and expanding customer base.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the chances for potential R&D sharing or bespoke R&D projects in 2026?
A:Peter Beetham and Gregory Gocal expressed optimism about significant opportunities in 2026 to expand R&D collaborations beyond their current focus on rice, canola, and soybean. They highlighted advancements in gene editing and regulatory tailwinds as catalysts for commercial products.
Q:What are your thoughts on when EU regulations for gene editing will be finalized?
A:Peter Beetham and Carlo Broos indicated that the EU regulatory process has accelerated, with final text expected by year-end 2025. They noted progress in legislation and industry support for gene editing technologies.
Q:How should we view the total addressable market for rice in Latin America, U.S., and India?
A:Peter Beetham and Gregory Gocal discussed the large market potential, with India having over 120 million acres of rice and being the second-largest exporter. In Latin America and the U.S., they have partnerships with 7 seed companies, addressing 5-7 million acres and targeting over $200 million in annual royalties.
Q:Why are HT traits different from Pod Shatter Reduction (PSR) traits, and why are they easier to fit into breeding programs?
A:Peter Beetham and Gregory Gocal explained that herbicide-tolerant (HT) traits are essential for weed management and have a well-established business model, making them easier to integrate into breeding programs. In contrast, PSR traits are more geographically confined and have limited market traction.
Q:What revenue expectations should we have for biofragrances in 2026 and beyond?
A:Peter Beetham stated that biofragrance revenues are expected to be in the single-digit millions in 2026, with potential to grow to $20-40 million. The fragrance market is over $65 billion, offering significant long-term opportunities.
Q:Are there ongoing expenses for pipeline traits like HT2, and how will they reflect in financials?
A:Peter Beetham confirmed that while resources for HT2 are minimal, the company is seeking partners for this multi-crop, multi-geography trait, which is expected to be significant in 2026.
Q:What are the regulatory requirements for selling in India, and how is the AgVaya relationship progressing?
A:Gregory Gocal highlighted India's acceptance of gene-edited crops, with the first gene-edited rice already planted. The AgVaya partnership is helping build relationships with seed companies and navigate regulatory requirements.
Q:Will biofragrance products hit store shelves in 2026, and what is the revenue ramp for 2027?
A:Peter Beetham and Carlo Broos confirmed that biofragrance products will be commercialized in 2026 in collaboration with a CPG company, with revenues still in single digits in 2027 before scaling up.
Q:What updates are there on European Parliament discussions regarding gene editing?
A:Peter Beetham reported progress in EU regulatory discussions, with final text expected soon. Key areas include amendments on gene edits, labeling, and patents, aligning with the company's practices.
Q:What financing options are being explored given the current cash position?
A:Peter Beetham and Carlo Broos stated that all financing options, both dilutive and non-dilutive, are being considered. They emphasized progress on milestones and cost-saving measures to support near-term operations.
Q:What advancements have been made in automation and real-time delivery systems for trait development?
A:Gregory Gocal detailed improvements in editing and regeneration frequencies, semi-automated processes for repetitive tasks, and the use of AI and ML to optimize editing choices and accelerate production pipelines.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the size and range of financing options being explored, stating only that all options are on the table. Additionally, they did not disclose which products biofragrances would be included in for 2026, citing limited guidance from their CPG partner.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO President
COO Director
California
Co Founder
FLAR
Founder Interim
India
Today
action
approval
capital allocation
cash usage
chemistry
collaboration
consolidation
customer agreement
customer base
date
decrease cost
expansion
facility
foundation
improvement
income
interest expense
launch
liability
market access
partner development
partnership
program milestone
recognition
relationship
runway opportunity
spring
track record
trait HT
trait program
validation
value crop
world rice
CBUS Transcript
Cibus, Inc. (CBUS) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call summary shows positive financial performance with increased revenue, gross margin, and net income. However, the lack of discussion on strategic initiatives, operational updates, and risk management creates uncertainty about future growth. The Q&A session did not provide additional insights, and no significant market-moving announcements were made. Overall, the financial health is solid, but the absence of strategic clarity limits the potential for a strong stock price reaction, leading to a neutral prediction.
Cibus, Inc. (CBUS) Q4 2025 Earnings Call Transcript
Unknown3-17
The earnings call presents a mixed picture. Financial performance shows cost reductions but a rising net loss, which is concerning. Product development and business updates are promising, with commercialization plans and regulatory advancements. However, Q&A reveals concerns about market adoption risks and lack of specific guidance on royalties. While the company has made progress in partnerships and regulatory approvals, the financial health and uncertain revenue growth temper the outlook, leading to a neutral sentiment.
Cibus, Inc. (CBUS) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call summary indicates a positive outlook with significant cost reductions, improved net loss, and strategic focus on future revenue streams, particularly from rice herbicide traits and biofragrance programs. The Q&A reveals optimism about R&D collaborations, regulatory progress, and market potential, despite some uncertainties in financing specifics. The strong potential for royalty revenue and commercial expansion, coupled with reduced expenses, suggests a positive stock movement over the next two weeks.
Cibus, Inc. (CBUS) Q2 2025 Earnings Call Transcript
Unknown8-15
The earnings call shows mixed signals: a slight revenue increase and reduced expenses are positives, but reliance on partner-funded programs and economic uncertainties pose risks. The Q&A reveals cautious optimism, with management avoiding specifics on key projects. The recent public offering improved cash reserves, but the stock may remain neutral due to uncertainties and lack of strong catalysts.
CBUS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
